Georgios V. Georgakis, MD, PhD
Dr. Georgios V. Georgakis is a surgical oncologist who cares for patients diagnosed with malignant peritoneal mesothelioma at Stony Brook Health in Stony Brook, New York. He is also a clinical professor of Surgery at the Renaissance School of Medicine at Stony Brook Health. His clinical interests include the treatment and management of malignant and benign tumors of the gastrointestinal tract, including liver, pancreas, esophagus, stomach, small bowel, appendix, and colon. He is skilled in standard open surgery and minimally invasive (laparoscopic and robotic) surgical techniques as well as regional perfusion therapies for treating late-stage and advanced cancers. He has significant training and experience in cytoreductive surgery with heated hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).[1]
Dr. Georgakis is also actively involved in treating patients diagnosed with sarcoma and melanoma, including performing sentinel lymph node biopsy and lymph node dissection, Robotic Whipple, and removing pancreatic tumors and other types of gastrointestinal (GI) tumors.[1]
Education and Career
Dr. Georgakis earned his medical degree at the University of Athens, which is also where he presented his PhD thesis, “The Role of PI3K-AKT-mTOR Pathway in the Pathogenesis of Hodgkin’s Lymphoma.” He completed his internship and residency training in General Surgery at the University of Connecticut and his fellowship training in Surgical Oncology at the University of Pittsburgh. He also completed a research fellowship at the University of Texas MD Anderson Cancer Center.[1]
Professional Memberships and Activities
In addition to being a Fellow of the American College of Surgeons, Dr. Georgakis is a member of several professional medical societies, including:[1]
- American Association for Cancer Research
- American College of Surgeons
- American Medical Association
- American Society of Clinical Oncology
- Americas Hepato-Pancreato-Biliary Association
- International Society of University Colon and Rectal Surgeons
- MD Anderson Alumni & Faculty Association
- Society for Immunotherapy for Cancer
- Society of American Gastrointestinal and Endoscopic Surgeons
- Society of Surgical Oncology
Dr. Georgakis also holds editorial positions with the Journal of Surgical Oncology, where he is a reviewer, and the World Journal of Colorectal Surgery, for which he serves on the editorial board.
Research
Dr. Georgakis’ research centers on the development of new technologies in cancer surgery. New drug development for regional perfusion therapies, including identification of molecular targets and their potential in combination with conventional chemotherapy, is also a focus.
Dr. Georgakis’ publications include:[1]
- Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33.
- Buglio D, Georgakis G, Younes A. Novel small-molecule therapy of Hodgkin lymphoma. Expert Rev Anticancer Ther 2007;7:735-40.
- Gao M, Lin M, Moffitt RA, Salazar MA, Park J, Vacirca J, Huang C, Shroyer KR, Choi M, Georgakis GV, Sasson AR, Talamini MA, Kim J. Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer. Br J Cancer 2019;120:88-96.
- Georgakis GV, Eisenberg DP, Piorkowski RJ, Macaulay WP, Jimenez RE. Effect of early enteral tube feeding on patient outcome following pancreaticoduodenectomy. Conn Med 2012;76:213-8.
- Georgakis GV, Li Y, Younes A. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9. Br J Haematol 2006;135:68-71.
- Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin’s lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-90.
- Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 2006;132:503-11.
- Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large-cell lymphoma irrespective of ALK expression. Exp Hematol 2006;34:1670-9.
- Georgakis GV, Li Y, Humphreys R, Andreeff M, O’Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-10.
- Georgakis GV, Younes A. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther2006;6:131-40.
